Skip to search formSkip to main contentSkip to account menu

Refractory B-Cell Non-Hodgkin Lymphoma

Known as: B-Cell Lymphoma Refractory, Refractory B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin's Lymphoma 
B-cell non-Hodgkin lymphoma that is resistant to treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Objective: To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment… 
2018
2018
e19550Background: Ibrutinib (Ibru) has shown therapeutic activity in patients (pts) with various B-cells malignancies, making it… 
2013
2013
Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been… 
2013
2013
Background Radioimmunotherapy (RIT) has been used to treat relapsed/refractory CD20+ Non-Hodgkin lymphoma (NHL). Myeloablative… 
2011
2011
The treatment outcomes for B-cell non-Hodgkin lymphoma have improved since targeted agents such as rituximab were incorporated… 
2006
2006
BACKGROUND & OBJECTIVE The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after… 
Review
2003
Review
2003
OBJECTIVE Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of the immune system, with more than 53,900… 
2000
2000
Primary B-cell lymphoma of the mediastinum is an aggressive non-Hodgkin's lymphoma with distinct clinicopathologic features…